metadichol licensing
DESCRIPTION
Metadichol is effective in hypertension and reducing insulin resistance and other key biomarkers that affect metabolic syndrome kidney function and inflammation. Metadichol appears to perform better than prescription drugs without any side effects. The mechanism of action has been elucidated and it is a unique one that nobody has published to date . Once a NDA is in place this can be disclosed and will help potential licensor understand the potential of Metadichol.A human pilot study on diabetic patients was carried out for 60 weeks and additional clinical studies are planned by our potential licensees in many parts of the world.TRANSCRIPT
METADICHOL® WORLD WIDE LICENSING OPPORTUNITY
One process many diseases
One approach many possible cures
For more Information, Contact usP.O. BOX 131! !CHAPPAQUA,, NY10514, USATEL: 914-671-0224! ! ! ! ! ! ! [email protected]
Nanorx Inc USA is pleased to an-nounce the availability of Metadi-chol ® a liquid formulation of sugar cane wax that can be added to exist-ing pharmaceutical drugs and Nu-traceuticals and water or juices to develop new and enhanced con-sumer products and pharmaceuticals with unique properties Metadichol is a unique Small Molecule Technol-ogy Formula (SMTF) with all natu-ral ingredients.
The primary source of the main in-gredient is sugar cane. The proprie-tary SMTF,* developed in the US and manufactured in Switzerland, delivers ingredient particles less than 70 nm in size in a stable prepa-ration. The formulation is stable at 25 degrees centigrade for over 2 years and maintains its size and sta-bility of ingredients. It contains no sugar, milk, egg, peanuts, yeast, glu-ten, artificial sweeteners, colors, fla-vors, or preservatives It is Made to US Pharmacopoeia (U.S.P.) quality. Laboratory and tested for purity and consistency.it has no known or re-ported toxicity.
Metadichol works on mitigating many diseases at a low dose and without any side effects. We have carried out studies of the effects of Metadichol in diabetic rats and in humans. Our results show that Meta-dichol is effective in reducing insu-
lin resistance and other key biomark-ers that affect metabolic syndrome and inflammation. Metadichol ap-pears to perform better than prescrip-tion drugs without any side effects.
A human pilot study on diabetic pa-tients was carried out for 60 weeks and additional clinical studies are planned by our potential licensees in many parts of the world.
We are now seeking interest from potential partners to License, manu-facture, market and distribute Meta-dichol and its family of related prod-ucts developed at Nanorx. Detailed clinical and mechanistic data is available once an NDA is in place.
Patent applications; A US and international patent appli-cations were published on Aug 26th, 2010 and February 23rd 2012. Na-tional Entry patents have been filed in EU, Japan, India, China, Austra-lia and other countries. US patent application 12/691706 published Aug 26th 2010US patent application 13/211132 published Feb 23rd 2012A 3rd patent in being filed and will appear early 2013.
0
38
75
113
ATOM BUCKYBALL DNA ATP SYNTHASE METADICHOL VIRUS
100.0
53.0
10.02.01.00.1
METADICHOL